D
Don Milligan
Researcher at Huntsman Cancer Institute
Publications - 11
Citations - 514
Don Milligan is an academic researcher from Huntsman Cancer Institute. The author has contributed to research in topics: Fludarabine & Chronic lymphocytic leukemia. The author has an hindex of 7, co-authored 11 publications receiving 491 citations.
Papers
More filters
Journal ArticleDOI
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Claire Dearden,Rachel Wade,Monica Else,Sue Richards,Don Milligan,Terry J. Hamblin,Daniel Catovsky +6 more
TL;DR: DAT status at the time of initiation of therapy provides a new prognostic indicator, although FC may protect against AHA, the largest prospective trial to examine the prognostic impact of both a positive direct antiglobulin test (DAT) and AHA.
Journal ArticleDOI
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia
David Oscier,Claire Dearden,Efrem Eren,Christopher Fegan,George A Follows,Peter Hillmen,Timothy M Illidge,Estella Matutes,Don Milligan,Andrew R. Pettitt,Anna Schuh,J. Wimperis +11 more
TL;DR: This research highlights the need to understand more fully the rationale behind the continued use of chemotherapy in patients with a prior history of cancer.
Journal ArticleDOI
T-Cell–Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma
Kirsty Thomson,Emma C. Morris,Don Milligan,Anne Parker,Ann Hunter,Gordon Cook,Adrian Bloor,Fiona Clark,Majid Kazmi,David C. Linch,Ronjon Chakraverty,Karl S. Peggs,Stephen Mackinnon +12 more
TL;DR: The excellent long-term survival with associated low rates of GVHD and the frequency and durability of DLI responses make this an extremely encouraging strategy for the treatment and potential cure of FL.
Journal ArticleDOI
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Michael Dennis,Nigel H. Russell,Robert Kerrin Hills,Claire Hemmaway,Nicki Panoskaltsis,Mary Frances McMullin,Lars Kjeldsen,Helen Dignum,Ian Thomas,Richard E. Clark,Don Milligan,Alan K. Burnett +11 more
TL;DR: Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial in older patients with relapsed/refractory disease, and in vitro data suggested synergy with cytarabine (Ara-C).
Journal ArticleDOI
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Peter Hillmen,Dena Cohen,Kim Cocks,Andrew R. Pettitt,Hazem A. Sayala,Andy C. Rawstron,Andy C. Rawstron,Daniel B. Kennedy,Christopher Fegan,Don Milligan,John Radford,Jane Mercieca,Claire Dearden,Raphael Ezekwisili,Alexandra Smith,Julia Brown,G. Booth,Abraham M. Varghese,Christopher Pocock +18 more
TL;DR: The addition of rituximab to FCM improves the response rates in relapsed CLL, resulting in more complete remissions and without additional safety concerns, and should be fully tested in a randomized Phase III trial.